CYP17A1 and prostate neoplasm: The most common therapy is based on enzyme inhibitor treatments and AR antagonists (Sumanasuriya and De Bono, 2018), one of which is an inhibitor of a P450 enzyme (CYP17) converting precursors into steroids, leading to the deprivation of locally produced androgen in prostatic tumors (Matsumoto et al., 2013).